U.S. Judge Lets Eli Lilly Continue Weight-Loss Drug Ads, Ruling Against Novo Nordisk

Eli Lilly Licenses SpeechDx Dataset for Alzheimer's Research

Eli Lilly and Company has entered a collaboration with the Alzheimer's Drug Discovery Foundation to license the SpeechDx dataset for use in Alzheimer's disease research.

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

Eli Lilly Announces Positive Phase 3 Results for Retatrutide in Type 2 Diabetes

Eli Lilly reported positive topline results from the TRANSCEND-T2D-2 Phase 3 trial, demonstrating that its investigational triple agonist retatrutide achieved superior A1C reduction and weight loss compared to Ozempic in adults with type 2 diabetes.

Eli Lilly Says Retatrutide Delivers More Than Double Ozempic’s Weight Loss in Late-Stage Diabetes Trial

Lilly’s retatrutide delivered more than double Ozempic’s weight loss in head-to-head diabetes trial

Novo Nordisk to Present New Semaglutide Clinical Data at The Liver Meeting 2026

Novo Nordisk announced it will present 12 new abstracts featuring real-world and clinical data on semaglutide at the American Association for the Study of Liver Diseases (AASLD) congress in November 2026.

Novo Nordisk To Present 12 New Semaglutide And MASH Research Abstracts At AASLD’s The Liver Meeting 2026